This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Mirati Therapeutics 将来の成長

Future 基準チェック /26

Mirati Therapeutics利益と収益がそれぞれ年間29.9%と42.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-155.2% 33%なると予測されています。

主要情報

29.9%

収益成長率

33.0%

EPS成長率

Biotechs 収益成長	28.5%
収益成長率	42.2%
将来の株主資本利益率	-155.2%
アナリストカバレッジ	Good
最終更新日	20 Dec 2023

今後の成長に関する最新情報

Recent updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Oct 05

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Jun 22

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

May 17

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Feb 01

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Dec 09

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Aug 08

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Jun 21

業績と収益の成長予測

NasdaqGS:MRTX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	495	-408	33	-94	8
12/31/2025	312	-556	-271	-261	13
12/31/2024	173	-670	-448	-447	17
12/31/2023	62	-694	-553	-551	17
9/30/2023	38	-726	-596	-594	N/A
6/30/2023	27	-738	-591	-588	N/A
3/31/2023	19	-737	-604	-600	N/A
12/31/2022	12	-741	-575	-571	N/A
9/30/2022	12	-738	-586	-580	N/A
6/30/2022	78	-645	-496	-489	N/A
3/31/2022	73	-634	-449	-439	N/A
12/31/2021	72	-582	-399	-389	N/A
9/30/2021	74	-483	-336	-327	N/A
6/30/2021	13	-491	-365	-357	N/A
3/31/2021	13	-407	-328	-323	N/A
12/31/2020	13	-358	-276	-272	N/A
9/30/2020	12	-329	-241	-237	N/A
6/30/2020	2	-296	-196	-193	N/A
3/31/2020	2	-259	-174	-172	N/A
12/31/2019	3	-213	-149	-148	N/A
9/30/2019	6	-169	-127	-127	N/A
6/30/2019	5	-142	-114	-114	N/A
3/31/2019	5	-125	-97	-97	N/A
12/31/2018	13	-98	-70	-70	N/A
9/30/2018	9	-88	-63	-63	N/A
6/30/2018	9	-77	-58	-58	N/A
3/31/2018	9	-67	-55	-54	N/A
12/31/2017	N/A	-70	-65	-65	N/A
9/30/2017	N/A	-72	-67	-67	N/A
6/30/2017	N/A	-75	N/A	-70	N/A
3/31/2017	N/A	-79	N/A	-69	N/A
12/31/2016	N/A	-83	N/A	-68	N/A
9/30/2016	N/A	-82	N/A	-68	N/A
6/30/2016	N/A	-81	N/A	-65	N/A
3/31/2016	N/A	-75	N/A	-58	N/A
12/31/2015	N/A	-65	N/A	-51	N/A
9/30/2015	N/A	-57	N/A	-43	N/A
6/30/2015	N/A	-46	N/A	-37	N/A
3/31/2015	N/A	-42	N/A	-34	N/A
12/31/2014	N/A	-44	N/A	-33	N/A
9/30/2014	N/A	-45	N/A	-32	N/A
6/30/2014	N/A	-65	N/A	-27	N/A
3/31/2014	N/A	-62	N/A	-31	N/A
12/31/2013	N/A	-53	N/A	-29	N/A
9/30/2013	N/A	-48	N/A	-27	N/A
6/30/2013	N/A	-24	N/A	-26	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MRTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MRTX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MRTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MRTXの収益 ( 42.2% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: MRTXの収益 ( 42.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MRTX 3 年以内に赤字になると予測されています。

This company has been acquired

Mirati Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 9.7% to US$60.00

Price target decreased by 8.0% to US$60.64

Consensus revenue estimates increase by 23%

Consensus revenue estimates decrease by 28%

Price target decreased to US$91.40

Consensus revenue estimates increase by 48%

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Price target increased by 9.7% to US$60.00

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

New major risk - Share price stability

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Insufficient new directors

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Second quarter 2023 earnings: EPS exceeds analyst expectations

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Price target decreased by 8.0% to US$60.64

New minor risk - Insider selling

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Chief Financial Officer recently sold US$172k worth of stock

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Insufficient new directors

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Consensus revenue estimates increase by 23%

Consensus revenue estimates decrease by 28%

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

CEO & Director recently sold US$135k worth of stock

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Founder recently sold US$170k worth of stock

Executive VP & Chief Scientific Officer recently sold US$104k worth of stock

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Price target decreased to US$91.40

Executive VP & Chief Scientific Officer recently sold US$156k worth of stock

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Founder exercised options and sold US$5.7m worth of stock

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Consensus revenue estimates increase by 48%

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Mirati: A Potential Blockbuster Stock, Will Need Patience

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati jumps 11% as Amgen meets key goal for rival cancer drug

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Mirati gains as Amgen posts new combination data for rival cancer drug

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘